Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (August 2026)
8 slides from Bayer's technical presentation, Aug 31, 2026
Slide 1: Cardiovascular-Kidney-Liver-Metabolic Overlap and Finerenone in Heart Failure with Preserved Ejection Fraction
Cardiovascular-Kidney-Liver-Metabolic Overlap and Finerenone in Heart Failure with Preserved Ejection Fraction John W. Ostrominski; Brian L. Claggett; Akshay S. Desai; Pardeep S. Jhund; Alasdair Henderson; Carolyn S.P. Lam; Michele Senni; Sanjiv J. Shah; Adriaan A. Voors; Faiez Zannad; Bertram Pitt;
Slide 2: Background
Background • HFpEF has become widely appreciated as a clinical syndrome characterized by multisystem dysfunction, especially along cardiovascular-kidney-liver-metabolic (CKLM) axes of risk • Clinical practice guidelines are increasingly constructed to provide more individualized, phenotype-oriented
Slide 3: FINEARTS-HF
FINEARTS-HF FINEARTS-HF was designed to evaluate the efficacy and safety of finerenone in people with HF and LVEF ≥40%, with or without diabetes, with or without chronic kidney disease Symptomatic HF (NYHA class II-V) with LVEF ≥40% Potassium >5.0 mmol/L Key Exclusion Key Inclusion Hospitalized, rec
Slide 4: Methods – CKLM Domains and Conditions
Methods – CKLM Domains and Conditions Primary Exposure: # of CKLM Domains at Baseline Cardiovascular Kidney Liver Metabolic • ASCVD • History of chronic • History of MASLD • History of type 2 • Prior MI kidney disease or MASH diabetes • Prior PCI OR OR OR • Prior CABG • Baseline eGFR <60 • Elevated
Slide 5: >99.9% of FINEARTS-HF Participants had ≥1 CKLM Domain Beyond HF
>99.9% of FINEARTS-HF Participants had ≥1 CKLM Domain Beyond HF
Slide 6: A Higher Number of CKLM Domains was Associated with Incremental Risk of CV Death & Total HF Events
A Higher Number of CKLM Domains was Associated with Incremental Risk of CV Death & Total HF Events Models adjusted for age, sex, self-reported race, smoking status, LVEF, recency of qualifying HF event prior to randomization, and log-transformed NT-proBNP
Slide 7: Relative Benefits of Finerenone Appeared Consistent, Irrespective of Baseline CKLM Status
Relative Benefits of Finerenone Appeared Consistent, Irrespective of Baseline CKLM Status Relative Effects Estimated Absolute Effects (3 Years) Overall Treatment Effect Estimate 0.84 (0.77-0.91) CKLM Subgroups 0.74 (0.58-0.94) 0.89 (0.80-1.01) 0.83 (0.73-0.95)
Slide 8: Key Findings and Conclusions
Key Findings and Conclusions • Coexistence between HFmrEF/HFpEF and other CKLM domains was effectively universal in FINEARTS-HF, globally and in all age groups • Higher CKLM overlap was incrementally associated with higher rates of adverse cardiovascular, kidney, metabolic, and mortality outcomes. •